R&D CENTER
HTBT's R&D center (about 2500 square meters) was completed and put into use at the end of 2010, and currently has 28 products/strengths under R&D. The small-scale production workshop of the R&D center is designed and built in accordance with the EU GMP and China's GMP standards and has been equipped with a whole set of imported bio-pharmaceutical R&D, production and testing facilities. The R&D center has about 20 researchers, of which doctors and masters account for nearly 70%. The company has initially formed a R&D team with senior engineers at the core and doctors and masters as the main force, and gathered a group of domestic and foreign industry experts and consultants, thus developing strong talent competitiveness. On January 27, 2011, the small-scale production workshop that developed and produced the first batch (second generation) of recombinant human insulin crystals of Anhui Province was inspected by the then Deputy Secretary of Anhui Provincial Communist Party Committee Sun Jinlong, and the Anhui Provincial Standing Committee Member and the Secretary of the Hefei Municipal Communist Party Committee Wu Cunrong, among other leaders.On June 8, 2012, the pilot plant developed and produced the first batch (third generation) of insulin analogues crystals of Anhui Province. During January 29-February 2, 2013 and October 21-24, 2013, the pilot plant of the R&D center accepted the EU QP audit by the UK's NSF-DBA and the conclusion was that the plant met the EU GMP standards.
International R&D Center
HTBT signed a cooperation framework agreement on joint R&D of bio-pharmaceutical technology and products with its partner Vannier, a Singaporean company. Based on Vannier's laboratory in Yavne, Israel and HTBT's R&D center, both sides set up a joint base in Yavne, Israel and Hefei, China respectively for joint development of bio-pharmaceutical technology and products. Vannier is a company dedicated to R&D of international advanced biotechnology. In 1980s, the company's R&D team members developed the second generation of insulin, and successfully transferred it to Poland's Bioton, Holland's Organon, India's SciGen and the United Arab Emirates' Julphar. In recent years, the company has been focused on the research of insulin analogs, and has accumulated rich experience.
Hefei Tianhui
Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) was founded on June 26, 2012, with a registered capital of 500 million yuan, and a registered address of Hefei Economic and Technological Development Zone in Anhui Province. HTIT's main business activities are incubation of science and technology enterprises, technology transfer, consulting and services, and R&D and sales of high and new technology and products, etc. The company is cooperating with foreign advanced biotechnology enterprises such as Israeli enterprises on the management and operation of professional incubators in the biological medicine field and has introduced foreign projects such as the world's most novel oral insulin capsules and a new generation of GLP-1 analogs. The 23000-square-meter incubator building of HTIT has been completed and is expected to be put into use in the middle of 2017.
